Systemic inflammation and imbalance between endothelial injury and repair in patients with psoriasis are associated with preclinical atherosclerosis

European Journal of Preventive Cardiology

Volumn 22, Issue 8, 2015, Pages 1027-1035

  Pirro, Matteo ^a   Stingeni, Luca ^a   Vaudo, Gaetano ^a   Mannarino, Massimo R ^a   Ministrini, Stefano ^a   Vonella, Marilisa ^a   Hansel, Katharina ^a   Bagaglia, Francesco ^a   Alaeddin, Abdalkader ^a   Lisi, Paolo ^a   Mannarino, Elmo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

atherosclerosis; C reactive protein; endothelial microparticles; endothelial progenitor cells; inflammation; Psoriasis

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CYCLOSPORIN; ETRETIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; AUTACOID;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE DURATION; ENDOTHELIAL MICROPARTICLE; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM INJURY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; WAIST CIRCUMFERENCE; AGED; ASYMPTOMATIC DISEASE; BLOOD; CAROTID ARTERY DISEASES; CASE CONTROL STUDY; IMMUNOLOGY; ITALY; MEMBRANE MICROPARTICLE; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PREVALENCE; PSORIASIS; RISK ASSESSMENT; RISK FACTOR; VASCULAR ENDOTHELIUM;

ADULT; AGED; ASYMPTOMATIC DISEASES; C-REACTIVE PROTEIN; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; CELL-DERIVED MICROPARTICLES; ENDOTHELIAL PROGENITOR CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; ITALY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; PSORIASIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84936934570     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487314538858     Document Type: Article

References (43)

1. Libby P,. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
2. Pirro M, Bergeron J, Dagenais GR,. Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. Arch Intern Med 2001; 161: 2474-2480.
3. Kaptoge S, Di Angelantonio E, Lowe G,. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. Lancet 2010; 375: 132-140.
4. Balci DD, Balci A, Karazincir S,. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol 2009; 23: 1-6.
5. El-Mongy S, Fathy H, Abdelaziz A,. Subclinical atherosclerosis in patients with chronic psoriasis: A potential association. J Eur Acad Dermatol Venereol 2010; 24: 661-666.
6. Troitzsch P, Paulista Markus MR,. Psoriasis is associated with increased intima-media thickness-the Study of Health in Pomerania (SHIP). Atherosclerosis 2012; 225: 486-490.
7. Antonucci VA, Tengattini V, Balestri R,. Intima-media thickness in an Italian psoriatic population: Correlation with lipidic serum levels, PASI and BMI. J Eur Acad Dermatol Venereol 2012; 31: 1-4.
8. Altekin ER, Koç S, Karaka MS,. Determination of subclinical atherosclerosis in plaque type psoriasis patients without traditional risk factors for atherosclerosis. Turk Kardiyol Dern Ars 2012; 40: 574-580.
9. Yiu KH, Yeung CK, Zhao CT,. Prevalence and extent of subclinical atherosclerosis in patients with psoriasis. J Intern Med 2013; 273: 273-282.
10. Pietrzak A, Bartosiska J, Chodorowska G,. Cardiovascular aspects of psoriasis: An updated review. Int J Dermatol 2013; 52: 153-162.
11. Dowlatshahi EA, Kavousi M, Nijsten T,. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: The Rotterdam Study. J Invest Dermatol 2013; 133: 2347-2354.
12. Reich K,. The concept of psoriasis as a systemic inflammation: Implications for disease management. J Eur Acad Dermatol Venereol 2012; 26: 3-11.
13. Armstrong AW, Harskamp CT, Armstrong EJ,. Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies. J Am Acad Dermatol 2013; 68: 654-662.
14. Sabatier F, Camoin-Jau L, Anfosso F,. Circulating endothelial cells, microparticles and progenitors: Key players towards the definition of vascular competence. J Cell Mol Med 2009; 13: 454-471.
15. Jourde-Chiche N, Dou L, Cerini C,. Vascular incompetence in dialysis patients-protein-bound uremic toxins and endothelial dysfunction. Semin Dial 2011; 24: 327-337.
16. Mannarino E, Pirro M,. Endothelial injury and repair: A novel theory for atherosclerosis. Angiology 2008; 59: 69S-72S.
17. Pirro M, Bocci EB, Di Filippo F,. Imbalance between endothelial injury and repair in patients with polymyalgia rheumatica: Improvement with corticosteroid treatment. J Intern Med 2012; 272: 177-184.
18. Rautou PE, Vion AC, Amabile N,. Microparticles, vascular function, and atherothrombosis. Circ Res 2011; 109: 593-606.
19. Boulanger CM, Scoazec A, Ebrahimian T,. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation 2001; 104: 2649-2652.
20. Sinning JM, Losch J, Walenta K,. Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. Eur Heart J 2011; 32: 2034-2041.
21. Yong PJ1, Koh CH, Shim WS,. Endothelial microparticles: Missing link in endothelial dysfunction? Eur J Prev Cardiol 2013; 20: 496-512.
22. Hill JM, Zalos G, Halcox JP,. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
23. Schmidt-Lucke C, Rössig L, Fichtlscherer S,. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: Proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005; 111: 2981-2987.
24. Pelletier F, Garnache-Ottou F, Angelot F,. Increased levels of circulating endothelial-derived microparticles and small-size platelet-derived microparticles in psoriasis. J Invest Dermatol 2011; 131: 1573-1576.
25. Martínez-Sales V, Vila V, Ricart JM, et al. Increased circulating endothelial cells and microparticles in patients with psoriasis. Clin Hemorheol Microcirc. Epub ahead of print 3 September 2013. DOI: 10.3233/CH-131766.
26. Batycka-Baran A, Paprocka M, Krawczenko A,. Reduced number of circulating endothelial progenitor cells (CD133+/KDR+) in patients with plaque psoriasis. Dermatology 2012; 225: 88-92.
27. Alberti KG, Eckel RH, Grundy SM,. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
28. Pearson TA, Mensah GA, Alexander RW,. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
29. Perk J, De Backer G, Gohlke H,. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Prev Cardiol 2012; 19: 585-667.
30. Pirro M, Schillaci G, Paltriccia R,. Increased ratio of CD31+/CD42- microparticles to endothelial progenitors as a novel marker of atherosclerosis in hypercholesterolemia. Arterioscler Thromb Vasc Biol 2006; 26: 2530-2535.
31. Dowlatshahi EA, van der Voort EA, Arends LR,. Markers of systemic inflammation in psoriasis: A systematic review and meta-analysis. Br J Dermatol 2013; 169: 266-282.
32. Combes V, Simon AC, Grau GE,. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999; 104: 93-102.
33. Rooney P, Connolly M, Gao W,. Notch-1 mediates endothelial cell activation and invasion in psoriasis. Exp Dermatol 2014; 23: 113-118.
34. Angelot F, Seillès E, Biichlé S,. Endothelial cell-derived microparticles induce plasmacytoid dendritic cell maturation: Potential implications in inflammatory diseases. Haematologica 2009; 94: 1502-1512.
35. Ablin JN, Goldstein Z, Aloush V,. Normal levels and function of endothelial progenitor cells in patients with psoriatic arthritis. Rheumatol Int 2009; 29: 257-262.
36. Rodríguez-Carrio J, de Paz B, López P,. IFNα serum levels are associated with endothelial progenitor cells imbalance and disease features in rheumatoid arthritis patients. PLoS One 2014; 9: e86069-e86069.
37. Ridker PM, Wilson PW, Grundy SM,. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109: 2818-2825.
38. Casas JP, Shah T, Hingorani AD,. C-reactive protein and coronary heart disease: A critical review. J Intern Med 2008; 264: 295-314.
39. Jeppesen J, Hansen TW, Olsen MH,. C-reactive protein, insulin resistance and risk of cardiovascular disease: A population-based study. Eur J Cardiovasc Prev Rehabil 2008; 15: 594-598.
40. Anand SS, Yusuf S,. C-reactive protein is a bystander of cardiovascular disease. Eur Heart J 2010; 31: 2092-2096.
41. Feng B, Chen Y, Luo Y,. Circulating level of microparticles and their correlation with arterial elasticity and endothelium-dependent dilation in patients with type 2 diabetes mellitus. Atherosclerosis 2010; 208: 264-269.
42. Leroyer AS, Tedgui A, Boulanger CM,. Role of microparticles in atherothrombosis. J Intern Med 2008; 263: 528-537.
43. Awan Z and Genest J. Inflammation modulation and cardiovascular disease prevention. Eur J Prev Cardiol. Epub ahead of print 7 April 2014. DOI: 10.1177/2047487314529350.